Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cerebral Edema ll: Pathophysiology01:22

Cerebral Edema ll: Pathophysiology

Vasogenic edema is a major form of cerebral edema characterized by abnormal accumulation of fluid in the brain’s extracellular space due to disruption of the blood–brain barrier (BBB). The BBB is a specialized structure composed of endothelial cells connected by tight junctions, supported by astrocytic endfeet and a basement membrane. Under normal conditions, it tightly regulates the movement of ions, proteins, and solutes between the bloodstream and brain parenchyma. When this barrier loses...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Increased Intracranial Pressure ll: Pathophysiology01:29

Increased Intracranial Pressure ll: Pathophysiology

Increased intracranial pressure (ICP) refers to a potentially life-threatening rise in pressure inside the skull. This usually happens when there is a major change in the volume of brain tissue, blood, or cerebrospinal fluid (CSF) — the three components inside the skull. According to the Monro-Kellie doctrine, if the volume of one component increases, the volumes of the other components must decrease to maintain normal pressure. If this does not happen, ICP rises.The process often begins with...
Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
Increased Intracranial Pressure l: Introduction01:14

Increased Intracranial Pressure l: Introduction

Intracranial hypertension is a sustained elevation of intracranial pressure (ICP) above 22 mm Hg. In supine adults, normal ICP is ~7–15 mm Hg.The rigid, nonexpandable cranium contains three components—brain tissue, blood, and cerebrospinal fluid (CSF)—that total ~1,700 mL in a typical adult: 1,400 mL brain (~80%), 150 mL blood (~10%), and 150 mL CSF (~10%). According to the Monro–Kellie doctrine, total intracranial volume is effectively fixed. When one component expands, CSF and venous blood...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Asymmetric Optic Disc Edema in Astronauts: A Narrative Review Proposing an Interplay Between Ocular Venous Congestion and Glymphatic Transport.

Life (Basel, Switzerland)·2026
Same author

Ocular Glymphatic Dysfunction as a Potential Link Between Obstructive Sleep Apnea and Retinal Structural Changes. Comment on Pusic Sesar et al. Multimodal Assessment of Ocular Parameters in Patients with Severe Obstructive Sleep Apnea with Emphasis on Retinal Structural Changes. <i>Life</i> 2025, <i>15</i>, 1307.

Life (Basel, Switzerland)·2026
Same author

An interpretable machine learning framework with data-informed imaging biomarkers for diagnosis and prediction of Alzheimer's disease.

Computerized medical imaging and graphics : the official journal of the Computerized Medical Imaging Society·2026
Same author

Cognitive correlates of cortical thickness, white matter volume, and resting-state connectivity in mild cognitive impairment.

Journal of Alzheimer's disease : JAD·2026
Same author

Limited evidence for heart rate variability as a predictor of cognitive and pathophysiological brain markers.

Journal of Alzheimer's disease : JAD·2025
Same author

Glymphatic transport and ocular diseases.

Progress in retinal and eye research·2025

Related Experiment Video

Updated: Jun 18, 2026

An Improved Method for Collection of Cerebrospinal Fluid from Anesthetized Mice
06:40

An Improved Method for Collection of Cerebrospinal Fluid from Anesthetized Mice

Published on: March 19, 2018

More advanced Alzheimer's disease may be associated with a decrease in cerebrospinal fluid pressure.

Peter Wostyn1, Kurt Audenaert, Peter Paul De Deyn

  • 1Department of Psychiatry, PC Sint-Amandus, Reigerlostraat 10, 8730 Beernem, Belgium. wostyn.peter@skynet.be.

Cerebrospinal Fluid Research
|November 18, 2009
PubMed
Summary
This summary is machine-generated.

Alzheimer's disease (AD) patients may have abnormal cerebrospinal fluid pressure (CSFP). Some show elevated CSFP suggesting early normal pressure hydrocephalus (NPH), while others exhibit very low CSFP, potentially linked to advanced AD and glaucoma risk.

More Related Videos

A Technique for Serial Collection of Cerebrospinal Fluid from the Cisterna Magna in Mouse
08:08

A Technique for Serial Collection of Cerebrospinal Fluid from the Cisterna Magna in Mouse

Published on: November 10, 2008

Related Experiment Videos

Last Updated: Jun 18, 2026

An Improved Method for Collection of Cerebrospinal Fluid from Anesthetized Mice
06:40

An Improved Method for Collection of Cerebrospinal Fluid from Anesthetized Mice

Published on: March 19, 2018

A Technique for Serial Collection of Cerebrospinal Fluid from the Cisterna Magna in Mouse
08:08

A Technique for Serial Collection of Cerebrospinal Fluid from the Cisterna Magna in Mouse

Published on: November 10, 2008

Area of Science:

  • Neurology
  • Ophthalmology
  • Neurosurgery

Background:

  • A study on Alzheimer's disease (AD) patients revealed varied cerebrospinal fluid pressure (CSFP) levels.
  • A subset of AD patients displayed elevated CSFP, consistent with early normal pressure hydrocephalus (NPH).
  • Conversely, a significant proportion of AD patients exhibited notably low CSFP.

Discussion:

  • The observed low CSFP in advanced AD patients warrants further investigation.
  • This finding may explain the frequent comorbidity between AD and glaucoma.
  • Lower CSFP in AD patients could increase trans-lamina cribrosa pressure, contributing to glaucomatous damage.

Key Insights:

  • Alzheimer's disease may be associated with abnormal cerebrospinal fluid pressure.
  • Very low CSFP in AD patients could be a marker for disease progression.
  • A potential link between AD, low CSFP, and glaucoma pathogenesis is proposed.

Outlook:

  • Further research is needed to confirm the association between advanced AD and reduced CSFP.
  • Investigating CSFP dynamics in AD could lead to novel diagnostic or therapeutic strategies.
  • Understanding the interplay between AD, CSFP, and glaucoma may improve patient outcomes.